After a couple of misfires, Pfizer has finally won FDA approval for its biosimilar of anemia drug Epogen/Procrit, a drug whose U.S. sales generated about $1.8 billion last year for partners Amgen and ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Retacrit will be priced 57.1% below the Wholesale Acquisition Cost (WAC) of Procrit and 33.5% below the WAC of Epogen, at $11.03 per 1000 Units/mL. In addition, Retacrit is indicated for the reduction ...
Dec. 2, 2005 -- The US Food and Drug Administration (FDA), Amgen Inc, and Ortho Biotech Clinical Affairs, LLC, have notified healthcare professionals via letter regarding revisions to the safety ...
The US Food and Drug Administration (FDA) has approved the first biosimilar erythropoiesis-stimulating agent. The reference product is epoetin alfa (Epogen/Procrit, Amgen). The new biosimilar is ...
THOUSAND OAKS, Calif., Sept. 24 /PRNewswire/ -- Amgen (Nasdaq: AMGN) announced today that certain lots of EPOGEN® and PROCRIT® (Epoetin alfa) vials are being voluntarily recalled from specialty ...
Epoetin alfa 10000 Units, 20000 Units; per mL; soln for IV or SC inj; contains albumin (human) and benzyl alcohol. Individualize (see full labeling for titration). CKD: initially 50–100 Units/kg 3 ...
Please provide your email address to receive an email when new articles are posted on . There are currently four FDA (Food and Drug Administration) approved erythropoiesis stimulating agents (ESAs) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback